| Autor: |
Akhila, Gandraju, A. G., Nagashree, K. M., Asha Spandana, S., Hemanth Kumar, H. S., Harshith, R., Vishnu Vardh, T., Shailesh |
| Předmět: |
|
| Zdroj: |
International Journal of Pharmaceutical Investigation; Oct-Dec2023, Vol. 13 Issue 4, p721-734, 14p |
| Abstrakt: |
Cancer is one of the leading causes of death across the world, which is caused by tumours. Breast Cancer (BC) is the most common cancer in women and the second most common cancer death in women. A variety of molecular biomarkers are being used to predict BC susceptibility, including hormone receptors for subtyping and several genes involved in genome maintenance. Hence, biomarkers have specific importance in translational and clinical development to improve diagnosis, prognosis, and treatment since they have advantages in detection time and energy efficiency. The impact of breast cancer, as well as BC risk factors, identification of high-risk groups, screening modalities, and guidelines for screening average-risk and high-risk individuals, therapy advancement using various types of biomarkers. This review describes the design, approval, and distribution of biomarkers and outlines the many types of biomarkers currently used in breast cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
